CIA
KALV

Choate Investment Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Choate Investment Advisors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$201K – 478
2026
Q1 		$201K Hold
10,000
– – ﹤0.01% 429
2025
Q4 		$162K Hold
10,000
– – ﹤0.01% 434
2025
Q3 		$122K Hold
10,000
– – ﹤0.01% 420
2025
Q2 		$113K Hold
10,000
– – ﹤0.01% 418
2025
Q1 		$115K Hold
10,000
– – ﹤0.01% 390
2024
Q4 		$84.7K Hold
10,000
– – ﹤0.01% 399
2024
Q3 		$116K Hold
10,000
– – ﹤0.01% 380
2024
Q2 		$118K Hold
10,000
– – ﹤0.01% 376
2024
Q1 		$119K Hold
10,000
– – ﹤0.01% 403
2023
Q4 		$123K Hold
10,000
– – ﹤0.01% 373
2023
Q3 		$96.3K Hold
10,000
– – ﹤0.01% 377
2023
Q2 		$90K Buy
+10,000
New +$92.2K ﹤0.01% 303

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Choate Investment Advisors's KALV Position: Q2 2026 in Review

Choate Investment Advisors sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 10,000 shares — an estimated $201K sold.

Choate Investment Advisors first reported a position in KALV in Q2 2023 and held it in 12 quarters. The position peaked at $201K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Choate Investment Advisors reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Choate Investment Advisors sold 10,000 KalVista Pharmaceuticals shares in Q2 2026, an estimated $201K.
  • Choate Investment Advisors first reported a position in KalVista Pharmaceuticals in Q2 2023 and held it in 12 quarters.
  • Choate Investment Advisors's KalVista Pharmaceuticals position peaked at $201K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Choate Investment Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.